By [Your Name/Journalistic Staff], reporting on the insights of Jana Wu, LCSW, LADC
For over 15 years, Jana Wu has sat across from patients in the trenches of mental health and substance use treatment. As she approaches the age of 50, a poignant, recurring question has begun to dominate her clinical observations: Why is the modern medical establishment—and society at large—so structurally predisposed to silence women’s distress before we have taken the time to fully understand its origins?
The answer to this question is increasingly being found in the rise of kratom. A tropical tree native to Southeast Asia, kratom has moved from the fringes of herbal supplement shops to the daily routines of countless women in their late 30s through their 60s. For these individuals, kratom is rarely a recreational choice; it is a functional necessity—a self-prescribed tool to navigate the relentless demands of the "sandwich generation" and the physiological upheaval of midlife.
The Chronology of Medicalized Suppression
To understand why women are reaching for substances like kratom, one must look at the historical trajectory of how female distress has been managed in the West. The clinical response to women’s anxiety did not emerge in a vacuum; it is part of a centuries-old narrative that prioritizes symptom management over root-cause analysis.
The 19th Century: Hysteria and Neurasthenia
In the 1800s, women presenting with anxiety, fatigue, insomnia, or unexplained pain were often diagnosed with "hysteria"—a catch-all term that pathologized the female experience. By the late 19th century, the diagnosis of "neurasthenia" (or "nervous exhaustion") became a common label for women struggling with the mounting pressures of domestic and social expectations. Treatment often involved bed rest, isolation, or, in more extreme cases, early forms of sedation.
The Mid-20th Century: The Era of "Mother’s Little Helper"
As pharmacology advanced, the approach shifted from "rest" to "tranquilization." The 1950s and 60s ushered in the age of the benzodiazepine. In 1963, Valium hit the market and quickly became a cultural staple. By 1966, the prevalence of these drugs in the lives of suburban women was so systemic that the Rolling Stones immortalized it in "Mother’s Little Helper," a song detailing the use of prescribed tranquilizers to endure the monotony and anxiety of domestic life.
The Modern Paradigm
Today, nearly 60 years after the release of that song, the medications have evolved, but the underlying systemic reliance on chemical "relief" remains. While modern medicine has undoubtedly made strides in recognizing hormonal shifts—such as perimenopause—the default response remains a clinical reflex to quiet the symptom as quickly as possible. When the distress persists, the patient is often left searching for alternatives, leading them to the unregulated market of supplements like kratom.
Supporting Data: The Anatomy of a Crisis
The emergence of kratom as a self-management tool is not merely a trend; it is a symptom of a larger systemic failure. Patients who utilize kratom often cite a specific triad of benefits: pain management, anxiety reduction, and, crucially, increased energy.
For the woman in her 40s or 50s, the "energy" benefit is often the primary motivator. Unlike traditional sedatives that might induce lethargy, these women report that kratom allows them to continue "functioning"—a word that carries heavy weight in the context of professional careers, childcare, and the caretaking of aging parents.
However, the data surrounding this consumption is concerning:
- Lack of Standardization: Unlike FDA-approved medications, kratom products are largely unregulated. Potency varies wildly between batches and suppliers, making it impossible for a consumer to know the exact dosage of active alkaloids they are ingesting.
- The "Poly-Substance" Risk: Clinical observations suggest that many individuals using kratom are doing so in conjunction with other substances, including alcohol, prescribed benzodiazepines, or opioids.
- The Physiology of Interaction: Combining kratom—which can have opioid-like effects—with other CNS depressants (like benzodiazepines) creates a significant risk of respiratory depression and excessive sedation. These are "silent" risks that are rarely addressed in the wellness-focused marketing of kratom products.
The Clinical Perspective: Whose Discomfort Are We Treating?
The most critical question for clinicians today is not "How do we stop women from using kratom?" but rather "Whose discomfort are we treating?"
Jana Wu, a clinician at Mountainside Treatment Center and a recognized expert on emerging substances, posits that when a provider is too quick to offer a "quick fix," they are often serving the societal desire for a woman to be "back to normal"—i.e., back to functioning without complaint—rather than addressing the genuine source of her suffering.
The "Functional" Trap
When a woman presents with a sudden onset of panic or an inability to sleep, the clinical impulse is often to prescribe an anxiolytic. If that fails, or if the side effects become intolerable, the woman may seek a "natural" alternative. Because kratom is marketed as an herb rather than a pharmaceutical, it sidesteps the stigma associated with psychiatric medication.
However, this perceived safety is an illusion. The transition from a prescription to an unregulated supplement represents a dangerous pivot: the patient has traded a regulated substance with a known, albeit risky, profile for an unpredictable substance with no oversight.
Implications for Future Care
Moving forward, the medical community must adopt a more holistic, investigative approach to women’s health.
1. Re-evaluating Midlife Care
Perimenopause and menopause are often treated as endocrine events rather than complex biopsychosocial transitions. A standard hormonal treatment plan may ignore the external stressors of a woman’s life. Clinicians must be willing to spend the time to map out the intersection of hormonal flux, career burnout, family trauma, and physiological symptoms.
2. Moving Beyond "Relief" as a Metric
If the goal of treatment is simply "the absence of symptoms," then both the physician and the patient have failed. True clinical success should be measured by the patient’s ability to understand their own body and its signals. We must shift the narrative from "curing" the woman’s distress to "interpreting" it.
3. Education and Harm Reduction
Given the prevalence of kratom, providers must be trained to screen for it specifically. Patients may not mention kratom in a medical intake because they do not view it as a "drug." By fostering a non-judgmental environment, clinicians can help patients understand the risks of interaction and, if necessary, support them in finding safer, more sustainable ways to manage their anxiety and pain.
Conclusion: A Call for Curiosity
The search for relief is a fundamental human drive. When we minimize a woman’s distress by immediately reaching for a prescription—or when we ignore her search for alternatives—we are ignoring the systemic pressures that make her life feel unsustainable.
Jana Wu’s work serves as a reminder that every story of substance use begins with a need. Sometimes that story starts years earlier, with a woman who was anxious, a provider who wanted to help, and a prescription that offered temporary relief. The tragedy occurs when that relief becomes the entirety of the treatment plan.
To break this cycle, we must trade the quick fix for the long, difficult work of curiosity. We must ask what is happening in the life surrounding the symptom. Only by validating the distress rather than just treating it can we hope to provide women with the care they actually need—not just the relief they are currently forced to settle for.
Jana Wu, LCSW, LADC, ICAADC, CASAC, is a clinician specializing in PTSD, anxiety, depression, and co-occurring disorders. She founded the country’s first clinician-led kratom support group and has been featured in The Wall Street Journal, Rolling Stone, and on NBC News. Her work continues to shed light on the complexities of substance use and the unique challenges faced by women in the modern healthcare system.
